AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...

AstraZeneca chief exec Pascal Soriot (pictured) said Britain should be trying to attract cash from the pharmaceutical sector ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.